

Phylogeny and Disease Association of Shiga Toxin-producing *Escherichia coli* O91

Alexander Mellmann, Angelika Fruth, Alexander W. Friedrich, Lothar H. Wieler, Dag Harmsen, Dirk Werber, Barbara Middendorf, Martina Bielaszewska, and Helge Karch

The diversity and relatedness of 100 Shiga toxin-producing *Escherichia coli* O91 isolates from different patients were examined by multilocus sequence typing. We identified 10 specific sequence types (ST) and 4 distinct clonal groups. ST442 was significantly associated with hemolytic uremic syndrome.

Shiga toxin-producing *Escherichia coli* (STEC) infections are public health concerns because of the severe illnesses they cause, such as hemorrhagic colitis and hemolytic uremic syndrome (HUS) (1). STEC constitute a heterogeneous group of bacteria abundant in the reservoir and in the environment (2). Transmission routes for human STEC infection are numerous and include contact with animal excreta, person-to-person transmission, and inadvertent ingestion of contaminated food and water. Many STEC serotypes have been recovered from humans (3,4). Among them, STEC O91 is the most common serogroup isolated from adult patients in Germany (5,6). The strains within this serogroup appear to be transmitted predominantly by food, because 1) food vehicles have been identified as the only risk factors for adults with sporadic STEC O91 infection in Germany (6); 2) O91 is the second most frequently isolated STEC serogroup in routine food samples (5); and 3) O91 is the only major STEC serogroup with no association between incidence of human infection and cattle density (7).

Whereas most human disease STEC serogroups possess, in addition to Shiga toxin, the *eae* gene encoding the adhesin intimin (3,4,8), STEC O91 consistently lack this

virulence determinant (8,9). Despite frequent isolation of STEC O91 from humans, the clonal relatedness of the serotypes of this serogroup is poorly understood. Therefore, we investigated 100 human STEC O91 isolates to determine the clonal structure of STEC O91 and its association with disease.

The Study

A total of 100 STEC O91 isolates were obtained from 1997 through 2007 from patients with HUS (n = 4), bloody diarrhea (n = 8), watery diarrhea without visible blood (n = 79), abdominal cramps without diarrhea (n = 1), or from asymptomatic carriers (n = 8); samples were from Germany (n = 96), Austria (n = 2; Austrian Reference Library, Innsbruck, Austria), Finland (n = 1; The National Public Health Institute, Helsinki, Finland), and Canada (n = 1; Public Health Agency of Canada, Guelph, Ontario, Canada). The 96 German O91 strains were recovered at the Institute of Hygiene, University of Münster, Münster, and the Robert Koch Institute, Wernigerode, Germany. The strains included all human isolates of this serogroup that were recovered during the study period in Germany and for which complete clinical information was available. The strains correspond to all O91 serotypes associated with human diseases from sporadic cases in Germany in that interval. Thirty-five strains have been described previously (4,8,10).

The age of patients from whom the STEC O91 strains originated ranged from 4 months to 89 years (median 28 years, interquartile range 12–38 years). The most severe symptom was recorded for each patient. Diarrhea was defined as ≥ 3 semisolid or liquid stools per day. Bloody diarrhea was defined as diarrheal stools containing blood visible to the naked eye. HUS was defined as a case of microangiopathic hemolytic anemia (hematocrit $< 30\%$ with peripheral evidence of intravascular hemolysis), thrombocytopenia (platelet count $< 150,000/\text{mm}^3$), and renal insufficiency (serum creatinine concentration greater than the upper limit of normal for age) (11). Asymptomatic carriers were apparently healthy persons without diarrhea; their stools were submitted as noted above.

Strains were isolated using Shiga toxin-encoding genes as diagnostic targets (12) and then serotyped phenotypically (13). All strains were verified as O91 by using PCR targeting *wzy*_{O91}, a component of the *rfb* gene cluster that synthesizes the O91 antigen (14). Multilocus sequence typing (MLST) and phylogenetic analysis were performed as described (4). All allelic sequences were deposited in the *E. coli* MLST database (<http://mlst.ucc.ie/mlst/dbs/Ecoli>). The minimum spanning tree was generated from all 100 O91 sequence types (STs) and compared with the HUS-associated enterohemorrhagic *E. coli* (HUSEC) collection (4) to display the distribution of the STs compared with all known STs associated with HUS.

Author affiliations: Institute of Hygiene and the National Consulting Laboratory on Hemolytic Uremic Syndrome, Münster, Germany (A. Mellman, A.W. Friedrich, D. Harmsen, B. Middendorf, M. Bielaszewska, H. Karch); Department of Periodontology, Münster (D. Harmsen); Robert Koch Institute, Wernigerode, Germany (A. Fruth); Free University Berlin, Berlin, Germany (L.H. Wieler); and Robert Koch Institute, Berlin (D. Weber)

DOI: 10.3201/eid1509.090161

Table 2. Univariate associations of STEC O91 of sequence type 442 with severe disease by use of exact logistic regression*

Severe disease	ST442, no. (%)	Non-ST442, no. (%)	Odds ratio	95% Confidence interval	p value
HUS	4 (20)	0 (0)	27.8†	3.29–∞	<0.01
BD	3 (15)	5 (6)	3.4	0.47–20.1	0.25
HUS or BD	7 (35)	5 (6)	7.8	1.83–36.6	<0.01

*Reference group consisted of persons who had nonbloody diarrhea or who were asymptomatic carriers. STEC, Shiga toxin-producing *Escherichia coli*; ST, sequence type; HUS, hemolytic uremic syndrome; BD, bloody diarrhea.

†Mean unbiased estimate.

severe disease, defined as either HUS or bloody diarrhea, was strong (OR 7.8, 95% CI 1.83–36.6, $p < 0.01$). Severe illness was noted for 7 (35.0%) of 20 patients infected by ST442 strains, but only for 5 (6.3%) of 80 patients infected by STEC O91 of other STs (Table 2). Patients with bloody diarrhea were younger (median age 12 years) than patients who had mild or no symptoms (median age 20 years). However, this difference was not observed for the 4 patients with HUS (median age 21 years); in this instance, 2 were adults, 1 was 39 months old, and 1 was unknown.

Conclusions

To gain insight into the clonal structure of STEC O91, we determined the relatedness of 100 strains isolated from patients and correlated the clonal lineage to the clinical outcome of the infection. MLST analysis divided the O91 isolates into 10 different STs, whereas classical serotyping identified only 4 complete serotypes (O- and H-antigen). Moreover, MLST was able to type all 25 nonmotile (H-) or nontypeable (Hnt) O91 strains. The analysis demonstrated that the *fumC* gene from the 7 genes used for MLST was the most heterogeneous and enabled strain differentiation into 5 different STs, among these ST442. It might therefore be a candidate for first-line single-locus sequence typing.

HUS or bloody diarrhea without HUS was significantly associated with ST442, which was represented by serotype O91:H21 only. However, Pradel et al. also reported a case of HUS associated with an O91:H10 isolate that could be differentiated from O91:H21 by using ribotyping (15). In our study, known virulence determinants such as cytolethal distending toxin V or Shiga toxin 2d activatable by elastase in O91:H21 strains (8,10) might contribute to the higher virulence of O91:H21 (ST442). However, further studies of the mechanisms behind the emergence of ST442 in Germany and additional analysis of global O91 isolates are needed. With the MLST approach described, trends and changes in STEC O91 epidemiology and human infections can be carefully surveyed.

Acknowledgments

We thank M. Karmali, D. Orth, and A. Siitonen for kindly providing O91 strains from their countries. We are also grateful to P. Tarr for critical reading of the manuscript.

This study was supported by grants from the Federal Ministry of Education and Research Network Zoonoses (grant nos.

01KI07124, 01KI07120, 01KI07127, 1368-763) and from the National Reference Laboratory Network of the Robert Koch Institute.

Dr Mellmann is a consultant for hygiene and infectious diseases at the University Hospital Münster. His professional interests include molecular identification and epidemiology of STEC and other bacterial pathogens.

References

- Karch H, Tarr PI, Bielaszewska M. Enterohaemorrhagic *Escherichia coli* in human medicine. *Int J Med Microbiol.* 2005;295:405–18. DOI: 10.1016/j.ijmm.2005.06.009
- Caprioli A, Morabito S, Brugere H, Oswald E. Enterohaemorrhagic *Escherichia coli*: emerging issues on virulence and modes of transmission. *Vet Res.* 2005;36:289–311. DOI: 10.1051/vetres:2005002
- Brooks JT, Sowers EG, Wells JG, Greene KD, Griffin PM, Hoekstra RM, et al. Non-O157 Shiga toxin-producing *Escherichia coli* infections in the United States, 1983–2002. *J Infect Dis.* 2005;192:1422–9. DOI: 10.1086/466536
- Mellmann A, Bielaszewska M, Köck R, Friedrich AW, Fruth A, Middendorf B, et al. Analysis of collection of hemolytic uremic syndrome-associated enterohaemorrhagic *Escherichia coli*. *Emerg Infect Dis.* 2008;14:1287–90. DOI: 10.3201/eid1408.071082
- Werber D, Beutin L, Pichner R, Stark K, Fruth A. Shiga toxin-producing *Escherichia coli* serogroups in food and patients, Germany. *Emerg Infect Dis.* 2008;14:1803–6. DOI: 10.3201/eid1411.080361
- Werber D, Behnke SC, Fruth A, Merle R, Menzler S, Glaser S, et al. Shiga toxin-producing *Escherichia coli* infection in Germany: different risk factors for different age groups. *Am J Epidemiol.* 2007;165:425–34. DOI: 10.1093/aje/kwk023
- Frank C, Kapfhammer S, Werber D, Stark K, Held L. Cattle density and Shiga toxin-producing *Escherichia coli* infection in Germany: increased risk for most but not all serogroups. *Vector Borne Zoonotic Dis.* 2008;8:635–43. DOI: 10.1089/vbz.2007.0237
- Bielaszewska M, Friedrich AW, Aldick T, Schurk-Bulgrin R, Karch H. Shiga toxin activatable by intestinal mucus in *Escherichia coli* isolated from humans: predictor for a severe clinical outcome. *Clin Infect Dis.* 2006;43:1160–7. DOI: 10.1086/508195
- Bettelheim KA. The non-O157 Shiga-toxigenic (verocytotoxigenic) *Escherichia coli*: under-rated pathogens. *Crit Rev Microbiol.* 2007;33:67–87. DOI: 10.1080/10408410601172172
- Bielaszewska M, Fell M, Greune L, Prager R, Fruth A, Tschäpe H, et al. Characterization of cytolethal distending toxin genes and expression in Shiga toxin-producing *Escherichia coli* strains of non-O157 serogroups. *Infect Immun.* 2004;72:1812–6. DOI: 10.1128/IAI.72.3.1812-1816.2004
- Tarr PI, Gordon CA, Chandler WL. Shiga toxin-producing *Escherichia coli* and haemolytic uraemic syndrome. *Lancet.* 2005;365:1073–86.
- Mellmann A, Bielaszewska M, Zimmerhackl LB, Prager R, Harmssen D, Tschäpe H, et al. Enterohaemorrhagic *Escherichia coli* in human infection: in vivo evolution of a bacterial pathogen. *Clin Infect Dis.* 2005;41:785–92. DOI: 10.1086/432722

13. Prager R, Strutz U, Fruth A, Tschäpe H. Subtyping of pathogenic *Escherichia coli* strains using flagellar (H)-antigens: serotyping versus *fliC* polymorphisms. *Int J Med Microbiol.* 2003;292:477–86. DOI: 10.1078/1438-4221-00226
14. Perelle S, Dilasser F, Grout J, Fach P. Identification of the O-antigen biosynthesis genes of *Escherichia coli* O91 and development of a O91 PCR serotyping test. *J Appl Microbiol.* 2002;93:758–64. DOI: 10.1046/j.1365-2672.2002.01743.x
15. Pradel N, Boukhors K, Bertin Y, Forestier C, Martin C, Livrelli V. Heterogeneity of Shiga toxin-producing *Escherichia coli* strains isolated from hemolytic-uremic syndrome patients, cattle, and food samples in central France. *Appl Environ Microbiol.* 2001;67:2460–8. DOI: 10.1128/AEM.67.6.2460-2468.2001

Address for correspondence: Alexander Mellmann, Institut für Hygiene, Universität Münster, Robert Koch Str 41, 48149 Münster, Germany; email: mellmann@uni-muenster.de

EMERGING INFECTIOUS DISEASES®



April 2008

Zoonotic Diseases



Search
past issues

EID
online
www.cdc.gov/eid